Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors

PURPOSE: In 2009, the US Food and Drug Administration (FDA) mandated a label change for leukotriene inhibitors (LTIs) to include neuropsychiatric adverse events (eg, depression and suicidality) as a precaution. This study investigated how this label change affected the use of LTIs and other asthma c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Ther
Auteurs principaux: Lu, Christine Y., Zhang, Fang, Lakoma, Matthew D., Butler, Melissa G., Fung, Vicki, Larkin, Emma K., Kharbanda, Elyse O., Vollmer, William M., Lieu, Tracy, Soumerai, Stephen B., Wu, Ann Chen
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5101625/
https://ncbi.nlm.nih.gov/pubmed/25920571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.03.027
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires